The effect of 3% diquafosol on the improvement of ocular surface post cataract surgery: A meta-analysis for time of intervention

Zhang, Yuhang; Ying, Qi; Xie, Xiaohang; Zhang, Fengyan

doi:10.1016/j.aopr.2022.100063

Cited by 4 publications

(3 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 20 , 21 , 22 Diquafosol has been found to stimulate not only fluid and mucin but also lipid secretion. 23 , 24 Reduced TBUT, decreased expression of conjunctival mucins in the tear fluid layer, and less conjunctival goblet cell density have been noted in patients with chronic forms of AC, including atopic keratoconjunctivitis and vernal conjunctivitis. 25 , 26 , 27 Despite the absence of impression cytology examinations for the assessment of inflammatory cell infiltrates and conjunctival goblet cells in this study, we considered the hypothesis that diquafosol improves tear film stability in AC patients with dry eye by means of liquid and mucin secretion stimulation as well as anti-inflammatory effects.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of 3% diquafosol combined with azelastine hydrochloride in allergic conjunctivitis patients with dry eye

Lin,

Zhu,

Yuan

et al. 2024

Advances in Ophthalmology Practice and Research

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Efficacy of 3% diquafosol combined with azelastine hydrochloride in allergic conjunctivitis patients with dry eye

Lin,

Zhu,

Yuan

et al. 2024

Advances in Ophthalmology Practice and Research

View full text Add to dashboard Cite

“…[20][21][22] Diquafosol has been found to stimulate not only uid and mucin but also lipid secretion. [23,24] Reduced TBUT, decreased expression of conjunctival mucins in the tear uid layer, and less conjunctival goblet cell density were noted in patients with chronic forms of AC, including atopic keratoconjunctivitis and vernal conjunctivitis. [25][26][27] Despite the absence of impression cytology examinations for the assessment of in ammatory cell in ltrates and conjunctival goblet cells in this study, we considered the hypothesis that diquafosol might improve the tear lm stability in AC patients with dry eye, by the means of liquid and mucin secretion stimulation, as well as anti-in ammatory effects.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of 3% diquafosol combined with azelastine hydrochloride in allergic conjunctivitis patients with dry eye

Zhu

Yuan

Mou

et al. 2023

Preprint

View full text Add to dashboard Cite

Purpose To evaluate the efficacy of a 3% diquafosol combined with azelastine hydrochloride ophthalmic solution in allergic conjunctivitis (AC) patients with dry eye. Methods The sample was composed of 158 eyes of 79 patients diagnosed with AC and dry eye. After enrollment, all subjects received azelastine hydrochloride (twice daily) combined with 3% diquafosol (six times daily) for four weeks. Scores of AC symptoms and signs, ocular surface disease index (OSDI), bulbar conjunctival hyperemia, tear meniscus height (TMH), non-invasive tear film break-up time (NIBUT), corneal fluorescein staining score, tear film break-up time (TBUT) and the Schirmer test were assessed at the baseline and two and four weeks after treatment. Results The symptom score of itching, foreign body sensation, and eye photophobia showed a significant decrease at two and four-week follow-up after treatment compared with baseline (p < 0.001). The eye tearing score showed a significant decrease at four weeks after treatment (p = 0.002). The AC sign score of follicles, conjunctival secretion and conjunctival hyperemia were significantly decreased at two and four weeks after treatment compare with baseline (p < 0.001, p = 0.001, respectively). After two and four weeks treatment, the OSDI score showed significantly decrease compared with baseline (26.53 ± 15.32 vs 17.25 ± 12.49, p < 0.001; 26.53 ± 15.32 vs 10.31 ± 8.54, p < 0.001). TMH, NIBUT and TBUT showed significantly improvement from baseline (TMH, 0.21 ± 0.06 vs 0.28 ± 0.07; 0.21 ± 0.06 vs 0.29 ± 0.07; NIBUT, 7.74 ± 3.35 vs 9.12 ± 3.09; 7.74 ± 3.35 vs 10.60 ± 2.86; TBUT, 3.53 ± 1.18 vs 4.53 ± 1.93; 3.53 ± 1.18 vs 4.53 ± 2.27; all p < 0.001). Conclusion 3% diquafosol combined with azelastine hydrochloride significantly improved subjective symptoms and objective signs in AC patients with dry eye.

show abstract

“…demonstrated that 3% diquafosol was effective in improving the ocular surface condition of patients after cataract surgery. 36 As for rebamipide, it was originally developed to treat gastric ulcers, but subsequent research has indicated that the topical application of rebamipide can effectively augment goblet cell count and stimulate the production of mucin-like proteins in both the lacrimal ducts and bulbar conjunctiva of human subjects. 37 …”

Section: Clinical Treatment Of Dedmentioning

confidence: 99%

Recent progress of nanomedicine in managing dry eye disease

Lv,

Li,

Zeng

et al. 2024

Advances in Ophthalmology Practice and Research

View full text Add to dashboard Cite

The effect of 3% diquafosol on the improvement of ocular surface post cataract surgery: A meta-analysis for time of intervention

Cited by 4 publications

References 16 publications

Efficacy of 3% diquafosol combined with azelastine hydrochloride in allergic conjunctivitis patients with dry eye

Efficacy of 3% diquafosol combined with azelastine hydrochloride in allergic conjunctivitis patients with dry eye

Efficacy of 3% diquafosol combined with azelastine hydrochloride in allergic conjunctivitis patients with dry eye

Recent progress of nanomedicine in managing dry eye disease

Contact Info

Product

Resources

About